Results 151 to 160 of about 579,279 (262)

Translating whole‐genome doubling into precision medicine in cancer

Molecular Oncology, EarlyView.
Whole‐genome doubling creates a WGD‐positive tumor state characterized by persistent chromosomal instability, karyotypic diversification, and cellular stress. These same biological pressures drive aggressive tumor evolution while exposing therapeutic vulnerabilities, providing a rationale for WGD‐informed precision medicine. Whole‐genome doubling (WGD)
Sejung Lee, Junghyeok Lim, Jinhyuk Bhin
wiley   +1 more source

Impact of expansive catastrophic plan eligibility on 2026 Marketplace enrollment. [PDF]

Health Aff Sch
Anderson DM, Nagy D, Drake C.
europepmc   +1 more source

Single‐cell DNA methylation profiling: Technologies, computation, and applications in precision oncology

Molecular Oncology, EarlyView.
Single‐cell DNA methylation (scDNAme) profiling maps epimutational clonal evolution, revealing mechanisms of malignancy and therapeutic resistance across diverse cancer types. By providing a high‐resolution landscape of intratumoral heterogeneity, these technologies empower precise patient stratification, guide the development of enhanced ...
Ik Soo Kim
wiley   +1 more source

Conditional Medicaid Expansion and Mental Health Outcomes in Georgia.

JAMA Netw Open
Onal SO, Prins SJ, Constantin J.
europepmc   +1 more source

Targeting transcription factors associated with hemoglobinopathies: Lessons from successful interventions and implications for cancer

Molecular Oncology, EarlyView.
This review summarizes the transcription factors, repressive chromatin‐modifying complexes, and epigenetic mechanisms that control fetal hemoglobin repression. Notably, many regulators of γ‐globin silencing also function in transcriptional and epigenetic networks that drive cancer, highlighting opportunities to translate advances in hemoglobinopathy ...
Meigen Yu, Puspa Das, Xing Zhang, Xiaodong Cheng   +3 more
wiley   +1 more source

CAR T-cell expansion after idecabtagene vicleucel is a predictor of outcomes in multiple myeloma. [PDF]

Hemasphere
Ferment B, Ouedrani A, Talbot A, Mouri N, Zarnitzky P, Stammler R, Vaugeois T, Diep A, Harel S, Royer B, Theves F, Forgeard N, Allain V, Caillat-Zucman S, Arnulf B.   +14 more
europepmc   +1 more source

CEACAM1 participation in breast cancer progression

Molecular Oncology, EarlyView.
In invasive breast cancer (BC), CEACAM1 shifts from an apical to a uniform membranous/cytoplasmic pattern, or is lost, as tumors dedifferentiate, inversely tracking the Ki‐67 proliferative index. In MCF‐7 cells, only CEACAM1‐4L suppresses proliferation, repressing cell cycle and growth factor genes.
Mykola Lyndin, Irina Kube‐Golovin, Anatolii Romaniuk, Gunther Wennemuth   +3 more
wiley   +1 more source

Dexamethasone prophylaxis for excessive lymphocyte expansion after cilta-cel in multiple myeloma. [PDF]

Blood Adv
Forsberg PA, Turner JA, Meyer M, Abbott D, Nicholson S, Schade H, Matous J, Gregory T.   +7 more
europepmc   +1 more source

PANoptosis in the pathogenesis of myelodysplastic syndromes

Molecular Oncology, EarlyView.
PANoptosis, a combination of three types of programmed cell death, is mediated by a large protein complex called a PANoptosome. In healthy bone marrow hematopoietic cells, PANoptosis is restricted by inhibitory signaling. In MDS, bone marrow cells become sensitive to the PANoptotic stimuli due to the aberrant inactivation of inhibitory signaling or ...
Rohit Thalla, Jyoti Lamichhane, Cameron Lewis, Peter Breslin, Jiwang Zhang   +4 more
wiley   +1 more source

Medicaid Expansion and Optimal Starts of Treatment for Incident Kidney Failure. [PDF]

Am J Kidney Dis
Roetker NS, Wetmore JB, Liu J, Guo H, Gilbertson DT, Johansen KL.   +5 more
europepmc   +1 more source